{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T16:25:39Z","timestamp":1764433539470,"version":"3.40.5"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.prro.2024.04.001","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T15:29:51Z","timestamp":1713281391000},"page":"301-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Management of Dry Eye Toxicity After Treatment With 177Lu-PSMA-617 Radioligand Therapy"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2441-9338","authenticated-orcid":false,"given":"Abigail","family":"Pepin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipose","family":"Mulugeta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil K.","family":"Taunk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2024.04.001_bib0001","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2024.04.001_bib0002","first-page":"284","article-title":"Comparison of prostate-specific membrane antigen expression levels in human salivary glands to non-human primates and rodents","volume":"35","author":"Roy","year":"2020","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.prro.2024.04.001_bib0003","doi-asserted-by":"crossref","first-page":"e8051","DOI":"10.15252\/emmm.201708051","article-title":"Salivary glands regenerate after radiation injury through SOX2-mediated secretory cell replacement","volume":"10","author":"Emmerson","year":"2018","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.prro.2024.04.001_bib0004","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0360-3016(92)90716-U","article-title":"The relationship between apoptosis and atrophy in the irradiated lacrimal gland","volume":"24","author":"Gazda","year":"1992","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.prro.2024.04.001_bib0005","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2967\/jnumed.122.264946","article-title":"Developing a patient-reported outcome measure for radionuclide therapy for prostate cancer","volume":"64","author":"Gudenkauf","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2024.04.001_bib0006","first-page":"837","article-title":"Response of the normal eye to high dose radiotherapy","volume":"10","author":"Parsons","year":"1996","journal-title":"Oncol Williston Park N"},{"key":"10.1016\/j.prro.2024.04.001_bib0007","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/0360-3016(94)90348-4","article-title":"Severe dry-eye syndrome following external beam irradiation","volume":"30","author":"Parsons","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2024.04.001_bib0008","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.radonc.2018.05.001","article-title":"Radiation dose constraints for organs at risk in neuro-oncology: The European Particle Therapy Network consensus","volume":"128","author":"Lambrecht","year":"2018","journal-title":"Radiother Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.prro.2024.04.001_bib0009","article-title":"Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study","volume":"40","author":"Herrmann","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2024.04.001_bib0010","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2024.04.001_bib0011","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-22-0236","article-title":"Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma\/paraganglioma","volume":"30","author":"Jimenez","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.prro.2024.04.001_bib0012","first-page":"738","article-title":"Salivary and lacrimal gland dysfunction (Sicca syndrome) after radioiodine therapy","volume":"42","author":"Solans","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2024.04.001_bib0013","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1007\/s00259-002-0969-0","article-title":"Long-term impairment of the lacrimal glands after radioiodine therapy: A cross-sectional study","volume":"29","author":"Zettinig","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.prro.2024.04.001_bib0014","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2967\/jnumed.108.061382","article-title":"Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation","volume":"50","author":"Grewal","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2024.04.001_bib0015","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850024000791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850024000791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T09:41:56Z","timestamp":1719394916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850024000791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1879850024000791"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2024.04.001","relation":{},"ISSN":["1879-8500"],"issn-type":[{"type":"print","value":"1879-8500"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Dry Eye Toxicity After Treatment With 177Lu-PSMA-617 Radioligand Therapy","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2024.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}